Kumazawa H, Imai N, Shioya M, Kato K, Fukaya Y, Noguchi A
Gan To Kagaku Ryoho. 1984 Aug;11(8):1655-62.
In 21 cancer patients receiving administration of FT-207 suppositories, we studied the concentration of FT-207 and 5-FU in the blood before surgery, and in the blood and tissues-tumor, normal and lymph node-sampled during surgery. These 21 cases were comprised of 12 cases of stomach cancer, 1 case of lymphosarcoma, 4 cases of rectal cancer, 2 cases of sigmoid cancer and 2 cases of breast cancer. Two hours after administration, the concentration of 5-FU reached its highest level and continued to maintain a level at which it could be expected to bring about clinical results even after four hours. The concentration of 5-FU in tumors and lymph nodes was high, especially in tumors compared with normal tissue (p less than 0.01). No difference could be found in the concentrations of FT-207 and 5-FU in serum and tissues from each 12 cases of stomach cancer, not only between of the early cancer and advanced cancer but also between patients more than 60 years old and those under 60 years old. No side-effects occurred in any case during suppository administration.
在21例接受FT - 207栓剂给药的癌症患者中,我们研究了手术前血液中FT - 207和5 - FU的浓度,以及手术期间采集的血液、肿瘤组织、正常组织和淋巴结中的浓度。这21例患者包括12例胃癌、1例淋巴肉瘤、4例直肠癌、2例乙状结肠癌和2例乳腺癌。给药两小时后,5 - FU浓度达到最高水平,甚至在四小时后仍持续维持在有望产生临床效果的水平。肿瘤和淋巴结中5 - FU的浓度较高,尤其是与正常组织相比,肿瘤中的浓度更高(p小于0.01)。在12例胃癌患者的血清和组织中,FT - 207和5 - FU的浓度在早期癌症和晚期癌症之间、60岁以上患者和60岁以下患者之间均未发现差异。在栓剂给药期间,任何病例均未出现副作用。